ArticleFrontiers in oncology2025
Efficacy and safety of the S-1, nab-paclitaxel, and gemcitabine triplet regimen in patients with resected pancreatic ductal adenocarcinoma.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the safety, feasibility, and efficacy of an S-1-based triplet regimen (with nab-paclitaxel and gemcitabine) as adjuvant therapy following curative resection for pancreatic ductal adenocarcinoma (PDAC). Methods: We retrospectively analyzed 3-year postoperative clinical data from 92 patients with PDAC who underwent curative resection between March 2020 and March 2022. Participants were allocated to either a control group (n = 40) receiving nab-paclitaxel plus gemcitabine (nab-P/GEM) or an experimental group (n = 52) receiving S-1 plus nab-paclitaxel plus gemcitabine. We compared overall survival (OS), disease-free survival (DFS), and adverse event (AE) incidence between groups. Results: The experimental group showed significantly longer median OS (28.9 vs. 20.9 months; HR 0.62, 95% CI 0.38-0.99; P = 0.049 by log-rank test) and DFS (19.5 vs. 13.6 months; HR 0.59, 95% CI 0.36-0.97; P = 0.036) compared with controls. The incidence of grade ≥3 AEs was significantly lower in the experimental group, including leukopenia (13.5% vs. 47.5%; P < 0.001) and neutropenia (15.4% vs. 70.0%; P < 0.001). Fewer patients in the experimental group required treatment discontinuation (1.9% vs. 12.5%) or dose modifications (13.5% vs. 65.0%). Conclusion: The S-1/nab-paclitaxel/gemcitabine triplet regimen appears to improve survival outcomes while demonstrating potentially favorable tolerability as adjuvant therapy for resected PDAC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.